Vvus stock prediction

image

Based on our forecasts, a long-term increase is expected, the “VVUS” stock price prognosis for 2025-12-10 is 0.972 USD. With a 5-year investment, the revenue is expected to be around +731.19%. Your current $100 investment may be up to $831.19 in 2027.

Where can you buy shares of VVUS?

Shares of VVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What was the earnings release for Vivus (VVUS)?

VIVUS, Inc. (NASDAQ:VVUS) released its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.31. The biopharmaceutical company had revenue of $19.63 million for the quarter.

How did Vivus’s stock split work?

How did VIVUS’s stock split work? VIVUS shares reverse split on the morning of Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 10th 2018.

Is Vivus’s PE (price/earnings) ratio good or bad?

The P/E ratio of VIVUS is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of VIVUS is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

image


How were VIVUS’s earnings last quarter?

VIVUS, Inc. (NASDAQ:VVUS) released its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.49) earnings p…


When did VIVUS’s stock split? How did VIVUS’s stock split work?

VIVUS’s stock reverse split on Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of sha…


Who are VIVUS’s key executives?

VIVUS’s management team includes the following people: John P. Amos , Chief Executive Officer & Director Mark K. Oki , Chief Financial & Account…


Who are some of VIVUS’s key competitors?

Some companies that are related to VIVUS include Johnson & Johnson (JNJ) , Eli Lilly and (LLY) , Pfizer (PFE) , AbbVie (ABBV) , Merck & Co., I…


What other stocks do shareholders of VIVUS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VIVUS investors own include Fulcrum Therapeutics (FULC) ,…


What is VIVUS’s stock symbol?

VIVUS trades on the NASDAQ under the ticker symbol “VVUS.”


How much money does VIVUS make?

VIVUS (NASDAQ:VVUS) has a market capitalization of $0.00 and generates $69.76 million in revenue each year. The biopharmaceutical company earns $-3…


How many employees does VIVUS have?

VIVUS employs 57 workers across the globe.


What is VIVUS’s official website?

The official website for VIVUS is www.vivus.com .


About VIVUS

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union.


Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!


VIVUS (NASDAQ:VVUS) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst’s rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).


Analyst Price Target Consensus

Sign-up to receive the latest news and ratings for VVUS and its competitors with MarketBeat’s FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company’s ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.


Average Share Price and Price Target by Month

The chart below shows how a company’s share price and consensus price target have changed over time. The dark blue line represents the company’s actual price. The lighter blue line represents the stock’s consensus price target.


VIVUS (NASDAQ:VVUS) Analyst Ratings Frequently Asked Questions

MarketBeat users like VIVUS stock less than the stock of other Medical companies. 63.26% of MarketBeat users gave VIVUS an outperform vote while medical companies recieve an average of 67.44% outperform votes by MarketBeat users.


Premium Research for VVUSQ

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.


Company Summary

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company’s lead investigational product in clinical development, Qnexa (TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009.

image

Leave a Comment